Foreign investors are stepping up acquisitions of Japanese drug makers. Under the Foreign Exchange and Foreign Trade Act (FEFTA), such…
BUSINESS
Shionogi Cuts Full-Year Guidance as Xofluza Sales Freefall
Sales of Shionogi’s novel influenza med Xofluza (baloxavir marboxil) plummeted 96.0% year over year in April-December following the medical community’s caveat issued over its resistance concerns, sending the company’s group revenue down 4.4% and triggering a downward revision on its…
To read the full story
Related Article
- Shionogi Suffers Lower Earnings as Xofluza Sales Dive 98.4% in FY2019
May 12, 2020
- Shionogi to Snap Up UMN Pharma to Bolster Vaccine Biz
October 31, 2019
- Shionogi’s Half-Year Sales Slip 4.4% after Xofluza Milestone Gain
October 31, 2019
- Academic Society Calls for Caution in Using Xofluza in Patients Under Age 12
October 28, 2019
- Shionogi’s Q1 Sales Sag 10.5% after Hefty Xofluza Milestone Gain
July 30, 2019
- Shionogi's FY2018 Sales Up 5.5% on HIV Royalties, Xofluza Notches 26.3 Billion Yen
May 10, 2019
BUSINESS
- Nihon Chouzai Tender Offer Completed, Set to Delist under Advantage Partners
September 18, 2025
- RaQualia’s Reflux Therapy Tegoprazan Debuts in India
September 18, 2025
- Eisai’s Etalanetug Snags FDA Fast Track Designation
September 18, 2025
- Daito Wins China Approval for Celecoxib, 2nd Generic in Market
September 18, 2025
- Alnylam Sees Japan Business Doubling as Amvuttra Expands into ATTR-CM
September 17, 2025
MSD’s new pulmonary arterial hypertension (PAH) therapy Airwin (sotatercept) hit the Japanese market in mid-August. It’s the kind of launch…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…